SUMMARY
INTRODUCTION
Tumor antigen-specific CD4 + T helper (Th) cells can induce a wide range of tumor antigen-specific cytotoxic T lymphocyte (CTL) responses via the maturation of dendritic cells (DCs), which avoid tumor evasion because of a mutation in a single target epitope (Kreiter et al., 2015) . In addition, Th cells can attenuate the immunosuppressive properties of the tumor microenvironment by altering the cytokine milieu (Kim and Cantor, 2014) . Therefore, adoptive T cell therapy using ex vivo expanded antigen-specific CD4 + Th cells may be a promising therapeutic strategy for refractory malignant tumors including hematological malignancies. However, clinical application is limited by the difficult isolation of CD4 + Th cells specific for relevant antigens and limited proliferative potential of these cells. This problem may be solved by using induced pluripotent stem cell (iPSC) technology. We and others have reported methods for establishing iPSCs from mature antigen-specific T cells and re-differentiating the iPSCs into CD8 + T cells or invariant T cells with the same T cell antigen receptor (TCR) as the original T cells Nishimura et al., 2013; Vizcardo et al., 2013; Wakao et al., 2013) . The proliferative potential of iPSCs may provide a sufficient number of CD4 + Th cells for cancer treatment.
CD40 ligand (CD40L), which is expressed on activated CD4 + Th cells, is critical for inducing DC maturation via the CD40-CD40L interaction (Bennett et al., 1997 (Bennett et al., , 1998 Boise et al., 1995; Ridge et al., 1998; Schoenberger et al., 1998; Summers deLuca and Gommerman, 2012; Wiesel and Oxenius, 2012) . Recently, the expression of CD40L on other types of immune cells known as innate lymphoid cells (ILCs) was reported (Magri et al., 2014; McKenzie et al., 2014; Summers deLuca and Gommerman, 2012) . ILCs play a fundamental role in the immune system not only by initiating, regulating, and resolving inflammation, but also by modulating adaptive immunity (Sonnenberg and Artis, 2015) . Although they lack TCRs, ILCs show T helper properties similar to Th1, Th2, Th17, and Th22 cells in terms of their cytokine profiles and transcription factors, which determine their development (McKenzie et al., 2014) . The contribution of ILCs to pathogen control and pathogenesis, along with their similarity and redundancy to acquired immune cells, are current of interest in immunology research (Cording et al., 2016) .
In the present study, we established iPSCs from a CD4 + Th1 clone specific for the junction region of BCR-ABL p210 (b3a2), a leukemia antigen, which is restricted by HLA class II (HLA-DR9) . We induced re-differentiation of iPSCs to T-lineage cells expressing HLA class II-restricted TCR (iPS-T cells). The gene expression profile of iPS-T cells differed from that of abTCR + T cells and resembled a subset of ILCs. By transferring CD4 molecule to iPS-T cells and optimizing the ex vivo culture conditions to induce iPS-T cells with high CD40L expression, we successfully generated innate lymphoid helper-like cells that activated leukemic antigen-specific CTLs via DC maturation in a TCR-dependent antigen-specific manner. The activated CTLs showed effective antileukemic activity.
Our findings indicate that functional helper-like cells can be acquired from iPS-T cells through genetic modification and purification of the population. Therefore, CD40L high CD4
+ iPS-T cells are a potential platform for novel adjuvant cell therapy against malignant tumors. 
RESULTS
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IgG CD3 T   SK   CD3   CD45   CD5   CD7   CD4   CD8   CD4   CD8  TCR-V 22   CD3   CD45   CD5   CD7   CD4   CD8   CD4   CD8  TCR-V 22 iPS-Ts (Table S3) expressed several ILC markers including CD56, CD161, NKG2D, c-Kit, NKp30, NKp44, NKp46, and DNAM-1 (Figure 1A , right panel). Despite their heterogeneity, the cells consistently expressed the same TCR as the original CD4 + Th1 clone (SK) ( Figure S2B ). Based on the expression of CD161 and c-Kit, iPS-T cells were divided into four subpopulations ( Figure S2C ), and their global RNA expression patterns were compared with those of natural killer (NK) cells, type 1 ILCs (ILC1s), type 2 ILCs (ILC2s), type 3 ILCs (ILC3s), abT cells, and gdT cells isolated from peripheral blood ( Figure S2D ). iPS-T cells had genetic properties more consistent with those of ILC1s, NK cells, and gdT cells than those of peripheral abT cells ( Figure S2E ; Table S2 ). The expression of genes related to T cell and ILC functions in iPS-T cells were similar to those in NK cells or ILC1s (Figures 1B and S2F; Table S3 ). Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed enrichment of genes related to ''NK cell-related cytotoxicity'' in iPS-T cells, NK cells, and ILC1s (Table S4 ). All subpopulations of iPS-T cells expressed relatively low levels of BCL11B, an essential transcription factor for T cell differentiation, compared with abT cells, but relatively high levels of ID2 and ZBTB16, which are transcription factors for ILCs ( Figures S2G and S4F ) (Naito et al., 2011; Spits et al., 2013) . All subpopulations commonly expressed ILC1-related genes, such as NCAM1, NCR1, NCR2, ICOS, and IL12RB2, but low levels of IL7R and IL1R, which are expressed on all ILCs except NK cells ( Figure 1D ) (Spits et al., 2013) . The ILC1/NK-like genetic properties of iPS-T cells, indicated by the relatively high expression of TBX21 and relatively low expression of GATA3 and RORC, were confirmed by the reads per kilobase million value and qRT-PCR analysis ( Figure 1C , and data not shown). As reported previously, our iPS-T cells exhibited TCR-independent NK cell-like cytotoxicity ( Figure S2H ) Yamada et al., 2016) . The iPS-T cells produced high levels of interferon-g (IFN-g), comparatively low levels of interleukin-4 (IL-4), and no IL-17, which are similar to the original CD4 + Th1 clone (SK) ( Figure 1E ). In addition, iPS-T cells were expanded by up to several thousand-fold by two rounds of phytohemagglutinin (PHA)-P stimulation ( Figure S2I ). These data suggest that iPS-T cells generated from the CD4 + Th1 clone have group 1 ILC-like properties despite their expression of TCR.
iPS-T cells (Mock iPS-T cells), and CD4-transduced iPS-T cells (CD4 + iPS-T cells). (G) Proliferative responses of Mock iPS-T cells and CD4
CD4 Modification Augments b3a2-Specific Responses in iPSC-Derived T Cells
During T cell activation, the binding of CD4 to HLA class II increases TCR signaling 30-to 300-fold (Janeway, 1992) , suggesting that CD4 is essential for the complete activation of Th cells. Because our iPS-T cells expressed HLA class II-restricted TCR from the original CD4 + Th1 clone (SK), we hypothesized that transduction of the CD4 gene in iPS-T cells results in enhanced TCR-dependent responses by peptide stimulation. We transduced the CD4 gene using a retroviral vector ( Figure 1F ). CD4-transduced iPS-T cells (CD4 + iPS-T cells) showed an antigen-dependent proliferative response and cytokine production restricted by HLA-DR9 ( Table S5 ). Gene ontology analysis revealed that categories related to cell proliferation were significantly upregulated in b3a2-stimulated CD4 + iPS-T cells compared with b3a2-stimulated Mock iPS-T cells ( Figure S5C ). These data collectively indicate that CD4 gene modification gives iPS-T cells an enhanced ability to exert b3a2 peptide-specific and HLA class II-restricted responses.
Identification of a CD40L high Population that
Efficiently Exerts Adjuvant Function CD40L expression on activated CD4 + Th cells is critical for the maturation of DCs, which provide costimulatory signals for effective activation and enhanced survival of antigen-specific CD8 + T cells (Bennett et al., 1997 (Bennett et al., , 1998 Boise et al., 1995; Ridge et al., 1998; Schoenberger et al., 1998; Wiesel and Oxenius, 2012) . In addition to CD4 + Th cells, IL-7 plus IL-1b primed murine ILC3 cells (Magri et al., 2014) and IL-2-activated human NK cells were reported to express functional levels of CD40L. We hypothesized that iPS-T cells express CD40L under stimulation by IL-2 receptor subunit g (common g chain), which binds to other ligand (IL-2, 4, 7, 9, 15, 21)-specific receptors. We detected preferential expression of CD40LG and simultaneous expression of partner cytokine receptors for common g chain including IL2RA, IL2RB, IL2RG, and IL15RA in the c-Kit + CD161 + subpopulation ( Figure S5D and data not shown). We cultured iPS-T cells in several combinations of common g chain cytokines and found that IL-2 in combination with IL-15 upregulated CD40L expression (Figures 2A and 2B ). independent cytotoxicity against THP-1, and the cytotoxicity against THP-1 was partially dependent on perforin and DNAM-1 ( Figure 4A ). iPS-T cells exert DNAM-1-and NKG2D-dependent cytotoxicity against K562 cells expressing both DNAM-1 ligand (PVR, nectin-2) and NKG2D ligands (MICA/B) . Despite the expression of both NK receptors, the iPS-T cells used in this study did not show NKG2D-dependent cytotoxicity ( Figure 4A ). This may be because of the reduced expression of NKG2D ligands (MICA/B) on THP-1 target cells ( Figure S7H ). 
WT1-Specific CTLs Primed By CD40L high CD4 + iPSCDerived T Cell/DC Interaction Exert Anti-leukemic Effects In Vivo
To examine whether primed WT1 peptide-specific CTLs exert anti-leukemic effects in vivo, WT1 epitope-expressing K562 cells were subcutaneously injected into NSG mice with or without WT1 peptide-specific CTLs. Tumor growth was monitored each week by bioluminescence imaging and external caliper measurements. In the presence of WT1 peptide-specific CTLs, tumor growth was significantly inhibited ( Figure 6A ) and the survival of mice was significantly prolonged ( Figure 6B We established iPSCs from b3a2-specific CD4 + Th cells (SK) and induced T-lineage cells (iPS-T cells) from these cells. Using the current differentiation protocol, the iPS-T cells spontaneously failed to express CD4 molecules, and their gene expression profiles were closer to those of ILC1s/NK cells than to those of abT cells, which may be partially explained by insufficient control of the transcription factor BCL11B for specification to the T cell-lineage . Bcl11b insufficiency is known to cause biased lineage-reprogramming from T cells to NK cells (a lineage of type 1 ILCs) in conditional knockout mice (Li et al., 2010) . Our iPS-T cells from multiple donors expressed ID2 and ZBTB16, but not BCL11B ( Figure S4F ). 
iPS-T cells and
DCs facilitates the production of chemokines to recruit CXCR3-expressing effector cells ( Figure 3B ). IFN-g production from these recruited effector cells activates DCs to amplify the production of chemokines (Groom and Luster, 2011) . This positive feedback loop pathway may further facilitate the recruitment and activation of effector cells in tumor tissues. In the actual leukemia environment, CD40L high CD4 + iPS-T cells may condition DCs to take up leukemia cells and cross-present leukemia-derived antigens, resulting in the activation of diverse CTLs that specifically recognize multiple leukemia antigens, a phenomenon known as epitope spreading. Chronic myelogenous leukemia (CML) cells carry a number of well-defined leukemia antigens including BCR-ABL, PR1, and WT1 (Molldrem et al., 2000; Rezvani et al., 2003) . Moreover, TKI treatment of CML induces various mutations in the BCR-ABL kinase domain because of resistance. The mutated antigens may then generate highly immunogenic neoepitopes (Cai et al., 2012) , and these neoepitopes are potential targets of epitope spreading by CD40L high CD4 + iPS-T cells. However, few suitable animal models are available that reproduce general reactions of human immune cells, particularly in HLA class II-restricted helper T cell/DCmediated CTL priming and subsequent tumor elimination. Animal models reconstituted with the human hematopoietic system, immune system, tumor xenograft, and iPS-T cells derived from the same patient may overcome this limitation in the future.
Our study is an initial step toward clinically applicable iPSC-derived T helper-like cell therapy. However, iPSCbased regenerative medicine is accompanied by challenges, such as the fact that these strategies are time-consuming and expensive. Compared with an autologous setting, the use of HLA-matched or homozygous HLA-type allogeneic iPSCs transduced with desired TCR (i.e., obtained TCR sequences from this research) may resolve this issue in the preparation of CD40L high CD4 + iPS-T cells (Neofytou et al., 2015) . In addition, reproducible production of CD4-expressing iPS-T cells is a prerequisite for their clinical application. In this study, CD4 gene transduction was performed after re-differentiation of iPSCs to T-lineage cells. Genome editing of iPSCs enables targeted insertion of the CD4 transgene into the downstream region of T cell-specific promoters, such as Lck promoter. Using such a system, it may be possible to establish an ideal iPSC clone expressing transgenes only at an ideal differentiation step when the promoter is activated. This may provide reproducible CD4-expressing iPS-T cells with safe profiles for clinical use. Moreover, establishing a good manufacturing practice-compliant manufacturing protocol using xenogeneicfree and feeder cell-free material is essential and currently under development (Fransen et al., 2011; Neofytou et al., 2015) .
In conclusion, we showed that iPS-T cells from CD4 + Th clone-derived iPSCs constitute a heterogeneous population of TCR-expressing group 1 ILC-like lymphoid cells. Gene modification and cell purification resulted in the acquisition of HLA class II-restricted TCR-expressing adjuvant cells that induce anti-leukemia effects via DC maturation. These results support iPS-T cells as a potential platform for novel adjuvant therapy for leukemia.
EXPERIMENTAL PROCEDURES
Peptide, Cytokines, and Chemicals Cr-release assay for 4 hr at the indicated E:T ratios. Data are representative of two independent triplicate experiments.
The following reagents were from commercial sources: recombinant human (rh) IL-2, rhIL-4, and rh granulocyte macrophage colony-stimulating factor (Primmune, Osaka, Japan); rhIL-7, rhIL-15, and rh fms-related tyrosine kinase 3 ligand (Flt-3L) (PeproTech, Rocky Hill, NJ, USA); rh basic fibroblast growth factor and PHA-P (Wako Pure Chemicals Industries, Osaka, Japan); rh vascular endothelial growth factor and rh stem cell factor (R&D Systems, Minneapolis, MN, USA); and penicillin-killed Streptococcus pyogenes (OK432) (Chugai Pharmaceutical, Tokyo, Japan).
Generation of Retrovirus for CD4 Transduction
The human CD4 gene was inserted into pDON-AI2 (Takara Bio, Shiga, Japan). Transient retroviral particles were produced in G3T-hi cells (Takara Bio), followed by transduction of PG13 cells to generate GaLV-pseudotyped retrovirus producer cells (Kaneko et al., 2001) .
Generation of iPSCs Derived from HLA Class IIRestricted Antigen-Specific CD4 + T Cell Clone HLA-DR9-restricted b3a2-specific CD4 + Th1 clone (SK) and HLA-DR53-restricted GAD65 113-131 peptide-specific CD4 + Th clone (SA32.5) (Tabata et al., 1998) were reprogrammed to iPSCs by transduction of reprogramming factors by the Sendai viral system using pSeV[KOSM302L] (kindly provided by Dr. Nakanishi, AIST, Tsukuba, Japan) as described previously Nishimura et al., 2013) . The iPSC clones were negative for residual transgenes, showed pluripotency characterized by the expression of pluripotency-related molecules and teratoma formation in immunodeficient mice, and were confirmed to have a normal karyotype ( Figure S1 ). The use of cells isolated from healthy adults was approved by the Ethics Committee of Kyoto University, and informed consent was obtained from all donors in accordance with the Declaration of Helsinki.
T Cell Differentiation from iPSCs and CD4 Transduction
We differentiated iPSCs into T cells using a previously described method (Nishimura et al., 2013) . In brief, clumps of iPSCs were transferred onto C3H10T1/2 feeder cells and cultured in EB medium containing rh vascular endothelial growth factor. On day 7, rh stem cell factor and rhFlt-3L were added to the culture. On day 14, hematopoietic progenitor cells were collected and transferred onto OP9-DL1 cells and co-cultured in OP9 medium in the presence of rhIL-7 and rhFLT-3L. On day 35, regenerated T cells were stimulated by PHA-P in the presence of rhIL-7 and rhIL-15 using allogeneic peripheral blood mononuclear cells (PBMCs) as antigen-presenting cells at 14-day intervals. Expanded iPSC-T cells (1 3 10 6 ) were transduced with human CD4 using the RetroNectin-bound virus infection method, in which retroviral solution was preloaded onto RetroNectin-coated plates, centrifuged at 2,000 3g for 2 hr at 32 C, and rinsed with 1.5% human serum albumin PBS, after which the cells were applied to the virus-preloaded plate for 20 hr. After 10 days of culture, a CD4-positive population (15%-35% of total cells) was sorted by flow cytometry and restimulated for expansion.
Functional Assay of T Cells
Cell proliferation was evaluated by the [ 3 H]thymidine incorporation assay, as described previously (Zhang et al., 2015) . Cytotoxic activity was measured using the 51 Cr-release assay, as described previously (Zhang et al., 2015) . Cytokine levels in the culture supernatants were evaluated by ELISA (hIFN-g: eBioscience, San Diego, CA, USA) or a bead-based multiplex immunoassay (BD Cytomertic Beads Array; BD Biosciences, Franklin Lakes, NJ, USA). 
CTL Priming and Cytotoxicity Assays
In Vivo Experiments
All in vivo animal studies were approved by the Animal Research Committee of Kyoto University. Six-week-old female NOD-SCID IL2Rgc null (NSG) mice were purchased from Charles River (Yokohama, Japan) and inoculated subcutaneously in the left shaved shank with mixtures of K562-Luc-A24-WT1 minigene (1.0 3 10 5 ) cells and either saline or WT1-specific CTLs (1.0 3 10 6 ). The mice were monitored for tumor growth and survival. Tumor growth was monitored weekly by bioluminescence imaging for 4 weeks and external caliper measurements until the mice died or were sacrificed when tumors exceeded 25 mm in diameter.
Retroviral Integration Site Analysis by Linear Amplification-Mediated PCR
Retroviral integration site analysis was performed using the Retro-X Integration Site Analysis Kit (Clontech, Mountain View, CA, USA) according to the manufacturer's instructions. 
Statistical Analysis
